JPMorgan (JPM) prices Review Notes linked to MerQube Index, maturity 2036
JPMorgan Chase Financial Company LLC is offering structured review notes linked to the MerQube US Tech+ Vol Advantage Index with an expected pricing date on or about July 14, 2026 and settlement on or about July 17, 2036. The notes are unsecured obligations of JPMorgan Financial and are fully and unconditionally guaranteed by JPMorgan Chase & Co. The Index level reflects a 6.0% per annum daily deduction and a notional financing cost applied to the QQQ Fund, which will reduce index performance versus an identical index without those deductions. The notes may be automatically called beginning on July 16, 2029 on specified Review Dates if the Index closing level is greater than or equal to the Call Value of 100.00% of the Initial Value, producing predefined Call Premium Amounts per $1,000 principal (starting at $360 on the first Review Date and up to $1,200 on the final Review Date). If not called, holders receive principal at maturity. The estimated value at issuance would be approximately $908.40 per $1,000, and the pricing supplement will include final Call Premium Amounts, the comparable yield, projected payment schedule and tax treatment.
Positive
- None.
Negative
- None.
Insights
Notes provide path to capped cash returns via scheduled call premiums but carry material index deductions and leverage risks.
The structure offers scheduled, increasing cash call premiums per $1,000 if the Index meets the Call Value on Review Dates, beginning with a $360 premium on the first Review Date. The Index applies a 6.0% per annum daily deduction and a notional financing cost to the QQQ Fund, which reduces net index performance and is reflected in pricing.
The Index’s target-volatility mechanism can employ up to 500% exposure, which magnifies moves and introduces volatility drag and leverage risk. Secondary-market liquidity, credit risk of the issuer/guarantor and the daily deductions are key factors affecting realized returns.
The issuer intends to treat the notes as contingent payment debt instruments for U.S. federal tax purposes.
The pricing supplement states the issuer intends to treat the notes as contingent payment debt instruments (CPDIs), requiring purchasers to accrue original issue discount at a comparable yield. The issuer will provide a comparable yield and projected payment schedule in the pricing supplement.
That treatment is based on current market conditions and is binding on holders absent proper IRS disclosure; the IRS could challenge the treatment, and alternative tax consequences are discussed in the supplement. Consult a tax adviser.